**Core tip:** This retrospective cohort chart review study provides novel data regarding the incidence of hepatocellular carcinoma (HCC) in the South of Brazil. Of 453 patients with cirrhosis attending a specialized reference clinic between March 2005 and March 2014, 75 (16.6%) developed HCC, with a cumulative incidence of 2.6%, 15.4% and 28.8% in the 1^st^, 5^th^, and 10^th^ year respectively. Early-stage HCC was more often detected in patients undergoing strict surveillance every 6 mo. Results from this study highlight the need for strict surveillance programs favoring early diagnosis and, probably, a better prognosis.

INTRODUCTION
============

Liver cancer is the second leading cause of cancer death worldwide; it is also the fifth most common cancer in men and the ninth in women. In 2012, an estimated 782000 new cases of liver cancer occurred in the world, with report of 745000 deaths\[[@B1]\]. Among primary liver malignancies, hepatocellular carcinoma (HCC) accounts for 70%-85% of cases, and is associated with chronic liver disease and/or cirrhosis in 70%-90% of cases\[[@B2],[@B3]\].

The burden of HCC varies with geographic location, especially when associated with cirrhosis\[[@B3]\]. Around 80% of cases occur in developing countries, and 55% in China alone\[[@B4]\]. In highly endemic areas, such as sub-Saharan countries and Asia, the annual incidence rate is around 30/100000 population\[[@B4]-[@B6]\]. Mediterranean countries (Italy, Spain and Greece) report intermediate incidence rates, with 10-20 cases/100000/year. An increase in the burden of HCC in low-incidence areas (Australia, North America, South America, and United Kingdom), with fewer than 5 cases/100000/ year, has also been recently noted. In these areas, the growing prevalence of hepatitis C virus (HCV) infection, alcohol consumption, and nonalcoholic fatty liver disease (NAFLD) are the main causes underlying the increasing number of HCC cases\[[@B2],[@B3],[@B7]-[@B11]\].

In Latin America, limited data are available on the incidence and population characteristics of patients with HCC\[[@B12]\]. In Brazil, a national epidemiological survey sponsored by the Brazilian Society for Hepatology\[[@B13]\] evaluated 1405 patients with HCC in 29 centers across the country. Using the Barcelona Clinic Liver Cancer (BCLC) staging classification\[[@B14]\], 43% of the individuals were diagnosed with early stage tumors; 35% with intermediate stage tumors; and 22% with advanced stage tumors. Also, 98% had cirrhosis, which was caused by HCV in 39% and heavy use of alcohol in 14%. In the South of Brazil, HCV has been identified as the main etiologic factor of cirrhotic outpatients\[[@B15]\].

Screening and surveillance of HCC using abdominal ultrasound have been shown to detect tumors at an earlier stage, increasing the odds of treatment and the adherence of health care services to current practice guidelines\[[@B16]-[@B19]\]. Nevertheless, epidemiological studies in the United States have shown that only 12% to 78.8% of patients receive routine surveillance\[[@B20],[@B21]\]; possible barriers to screening and surveillance include socioeconomic factors and the lack of specific health policies for HCC\[[@B22]\].

The objective of the present study was to determine the incidence of HCC and the impact of HCC surveillance on early diagnosis and survival of cirrhotic outpatients attending a tertiary hospital clinic in the South of Brazil.

MATERIALS AND METHODS
=====================

We carried out a retrospective cohort chart review study including all patients aged 18 years or older diagnosed with cirrhosis attending a specialized reference clinic (Complexo Hospitalar Santa Casa, Porto Alegre, Brazil) between March 2005 and March 2014. Exclusion criteria were HIV coinfection, previous organ transplantation, diagnosis of HCC at the first clinic appointment, incomplete medical records, or follow-up of less than 1 year. The diagnosis of cirrhosis was based on clinical, laboratory, and on ultrasonographic and/or upper GI endoscopic features. Those patients whose diagnosis remained inconclusive, percutaneous liver biopsy were carried out.

All patients underwent screening and surveillance for HCC, with abdominal ultrasound and serum alpha-fetoprotein (AFP) determination every 6 mo. Computed tomography (CT) or abdominal magnetic resonance imaging (MRI) with contrast were performed in all patients with evidence of nodular lesion measuring ≥ 1 cm in diameter on ultrasound\[[@B23]\].

HCC diagnosis was based on typical findings on contrast-enhanced CT or abdominal MRI - early arterial phase enhancement followed by rapid washout at the late portal/venous phase. Inconclusive cases were referred for biopsy and histological evaluation\[[@B23]\]. Patients with a diagnosis of HCC were classified according to BCLC criteria\[[@B14]\].

All charts were reviewed for selection of study variables and outcomes during the study period, considering the data available for the first and the last consultations. The following variables were analyzed: age, sex, etiology of liver disease, Child-Turcotte-Pugh\[[@B24]\] score, Model for End-Stage Liver Disease score\[[@B25]\], use of statins, and serum levels of AFP.

The establishment of alcohol consumption was made through self-report of regular drinking, in a daily basis. Heavy use of alcohol was considered when alcohol consumption was greater than 40 g per day for men and women.

All patients received specialized treatment according to the etiology of liver disease and risk factors identified. Obese and/or NAFLD patients were referred to a Clinical Nutrition outpatient clinic. Those with alcohol dependency were headed for a public specialized psychiatric service and encouraged to attend support groups to stop drinking.

The patients were divided into two groups: with or without HCC. To compare the groups in terms of continuous variables with normal distribution, Student's *t* test was used. Mann-Whitney's test was used for comparison of variables with non-Gaussian distribution. For the comparison of categorical variables, the *χ*^2^ test and Fisher's exact test were used. To evaluate the performance of AFP as a diagnostic tool, in patients with HCC, sensitivity, specificity, post-test probability, and likelihood ratio were calculated for different serum level ranges. These data were also represented as ROC curves and box plots generated with log-transformed values. Kaplan-Meier analysis was performed to examine cumulative incidence and survival in the 10-year follow-up period, with statistical significance calculated using the log-rank test. HR with 95%CI was calculated using a Cox regression model. Significance level was set at α = 5%.

Microsoft^®^ Office Excel 2010 was used to store data, and the Statistical Package for the Social Sciences v. 22.0 (IBM^®^ SPSS) was used for analysis of results. The normality of data distribution was determined using the Kolmogorov-Smirnov test. Quantitative variables with normal distribution were expressed as mean and standard deviation; variables with non-normal distribution were expressed as median and interquartile range. Simple and relative frequencies were used for categorical variables.

The research protocol was approved by the Research Ethics Committee at Universidade Federal de Ciências da Saúde de Porto Alegre (protocol 367511/2011, approval report 14/2014).

RESULTS
=======

Of 738 eligible patients, the following were excluded: 105 with incomplete medical records, 88 with non-cirrhotic portal hypertension, 54 who were lost to follow-up, and 14 with HIV co-infection. Of the remaining 477 cirrhotic patients, 24 were diagnosed with HCC at the first clinic appointment and were thus excluded from the study. Thus, the final sample included 453 patients.

During follow-up, 75 patients (16.6%) were diagnosed with HCC. Median follow-up for this group was 15.7 mo. Among the 378 patients who did not develop HCC, median follow-up was 58.4 mo. Table [1](#T1){ref-type="table"} shows demographic and clinical data of the groups with and without HCC.

###### 

Demographic and clinical characteristics of cirrhotic outpatients attending a hospital clinic in the South of Brazil *n* (%)

  **Characteristic**        **HCC**           **Without HCC**   ***P* value**
  ------------------------- ----------------- ----------------- ---------------
  Age (yr)                  54.9 ± 10.7       53.2 ± 12.2       0.23
  Male sex                  44 (58.7)         217 (57.4)        0.90
  Cirrhosis etiology                                            0.27
  HCV                       35 (46.7)         132 (34.9)        
  Alcohol                   16 (21.3)         93 (24.6)         
  HCV + alcohol             15 (20.0)         74 (19.6)         
  HBV                       2 (2.7)           3 (0.8)           
  HBV + alcohol             0 (0.0)           5 (1.3)           
  NAFLD                     1 (1.3)           7 (1.8)           
  Cryptogenic               1 (1.3)           12 (3.2)          
  Other                     5 (6.7)           52 (13.8)         
  Baseline Child-Pugh       *n* = 74          *n* = 377         0.81
  A                         45 (60.8)         229 (60.7)        
  B                         22 (29.7)         119 (31.6)        
  C                         7 (9.5)           29 (7.7)          
  End-of-study Child-Pugh   *n* = 75          *n* = 367         0.38
  A                         30 (40.0)         168 (45.8)        
  B                         25 (33.3)         127 (34.6)        
  C                         20 (26.7)         72 (19.6)         
  Baseline MELD             *n* = 60          *n* = 292         
                            11.2 (6; 25)      12.0 (6 ;27)      0.12
  End-of-study MELD         *n* = 71          *n* = 330         
                            13.4 (6; 31)      13.1 (6; 45)      0.65
  Baseline AFP, ng/mL       *n* = 69          *n* = 261         
                            6.1 (3.7; 19.0)   4.0 (1.5; 8.0)    0.01
  End-of-study AFP, ng/mL   *n* = 57          *n* = 286         
                            16 (4.9; 187.0)   4.0 (2.5; 7.8)    \< 0.001

Other, autoimmune hepatitis, primary biliary cholangitis, hemochromatosis, primary sclerosing cholangitis, alpha-1 antitrypsin deficiency; MELD and AFP expressed as median and interquartile range (25%-75%). HCV: Hepatitis C virus; HBV: Hepatitis B virus; NAFLD: Nonalcoholic fatty liver disease; MELD: Model for End-Stage Liver Disease; AFP: Alpha-fetoprotein.

AFP levels were available for 343 patients, of which 57 had a diagnosis of HCC (16.7%). Baseline and end-of-study AFP levels were significantly different between patients with and without HCC. Stratification of serum AFP levels into four ranges (Figure [1](#F1){ref-type="fig"} and Table [2](#T2){ref-type="table"}) revealed a trend for AFP \> 20 ng/mL to predict HCC. The highest diagnostic probability was observed for AFP levels ≥ 50 ng/mL (Table [2](#T2){ref-type="table"}). Accuracy of AFP was measured by the area under the ROC curve, whose value was 0.769 (95%CI: 0.70-0.84).

![Log-transformed alpha-fetoprotein values at the end of the study in patients with and without hepatocellular carcinoma.](WJG-22-10219-g001){#F1}

###### 

Pre-test probability, likelihood ratio, post-test probability, sensitivity, and specificity of alpha-fetoprotein ranges to predict hepatocellular carcinoma

  **AFP level (ng/mL)**   **Pre-test probability**   **LR+**   **Post-test probability**   **Sensitivity**   **Specificity**
  ----------------------- -------------------------- --------- --------------------------- ----------------- -----------------
  \< 6.0                  16.60%                     0.50      9.1%                        66.7%             66.3%
  6-19.9                  16.60%                     1.00      16.6%                       45.6%             89.3%
  20-50                   16.60%                     1.31      20.8%                       35.1%             96.1%
  \> 50                   16.60%                     10.03     66.8%                       35.1%             96.1%

LR: Likelihood ratio; AFP: Alpha-fetoprotein.

The 10-year cumulative incidence of HCC was analyzed using a Kaplan-Meier curve (Figure [2](#F2){ref-type="fig"}). During this 10-year period, 453 patients were followed-up. The estimated incidence of HCC was 2.6% in the 1^st^ year, 15.4% in the 5^th^ year, and 28.8% in the 10^th^ year.

![Ten-year cumulative incidence of hepatocellular carcinoma in cirrhotic outpatients.](WJG-22-10219-g002){#F2}

Among 419 patients who reported not using statins, 73 (17.4%) had HCC, *vs* only 1 patient among 34 using statins (2.9%), *P* = 0.028.

Survival analysis showed median survival of 234 mo (19.5 years) for the group without HCC and 17.6 mo (1.5 year) for patients with HCC. At the end of 10 years, none of the HCC patients were alive, whereas 55.8% of the patients without HCC were still living (*P* \< 0.001, Figure [3](#F3){ref-type="fig"}).

![Kaplan-Meier cumulative survival curve in patients with hepatocellular carcinoma and 10-yr follow-up. HCC: Hepatocellular carcinoma.](WJG-22-10219-g003){#F3}

BCLC staging of HCC at the time of diagnosis showed early stage tumors in 40 (53.3%) patients, intermediate stage tumors in 26 (34.6%) patients, and advanced tumors in 9 (12%) patients. Only 50.7% of individuals with HCC had undergone ultrasound surveillance every 6 mo. The analysis of tumor staging (early *vs* non-early) according to frequency of ultrasound surveillance showed a higher number of cases diagnosed with early stage tumors in patients with surveillance every 6 mo or less (*P* = 0.05). However, survival was not different between patients with early stage *vs* non-early stage tumors \[HR = 0.54 (0.15-1.89), *P* = 0.33\].

DISCUSSION
==========

Given the impact of HCC incidence on patients with cirrhosis, as well as the scarcity of data regarding this population in Latin America, we set out to determine the incidence of HCC and the role of a surveillance program in a cohort of cirrhotic patients attending an outpatient clinic in the South of Brazil, region predominantly composed by European descendants.

In this study, 75 of 453 (16.6%) patients developed HCC over 10 years - a higher incidence than the 8.1% observed in a cohort followed-up in the Southeast of Brazil\[[@B26]\]. Data from other countries also reveal higher incidences in various populations, such as 17.5% in the United States\[[@B27]\] and 27% in an Italian cohort\[[@B28]\]. Because Brazil is a country of continental proportions, the higher incidence detected in the South may be explained by geographic and/or racial heterogeneity, as well as specificities related to risk factors and access to health care services for screening, diagnosis, and follow-up. The predominance of the male sex and the mean age at diagnosis were similar to those described in other national\[[@B13],[@B29],[@B30]\] and international\[[@B12],[@B31],[@B32]\] studies.

In the present study, the etiology of liver disease was similar in patients with or without HCC, with HCV and alcohol being the main etiologic agents. In Brazil, chronic HCV infection and alcohol consumption are a major public health problem\[[@B33],[@B34]\]; nevertheless, in some regions HBV is still an important cause of cirrhosis and HCC\[[@B35]\]. Llovet et al\[[@B36]\] have shown that in Europe and North America, HCV and alcohol are more frequently associated with HCC than HBV, differently than what occurs in Asia and Africa.

The establishment of surveillance programs for patients with chronic liver disease gained momentum after the study by Zhang et al\[[@B37]\], which showed that performing abdominal ultrasound and AFP testing every 6 mo was capable of identifying patients in earlier stages of the disease, increasing survival in up to 37% of cases.

A major objective of follow-up of patients with cirrhosis is the screening and surveillance of HCC according to various consensus statements and guidelines\[[@B31],[@B38]-[@B40]\]. Brazilian Society for Hepatology\[[@B41]\] has recently recommended the performance of abdominal ultrasounds every 6 mo, with measurement of AFP strictly in sites where physicians who are experienced in ultrasound are not available.

AFP was recognized in the 1970s as a tumor marker for diagnosis of HCC. This biomarker lost ground after many studies showed low sensitivity and specificity for detection of early stage tumors, leading to the exclusion of AFP dosing from the main consensus statements\[[@B31],[@B38],[@B40]\]. Despite the debate, the Asian Pacific Association for the Study of the Liver and the Japan Society of Hepatology kept the recommendation for serial AFP measurement, based on the understanding that this information could complement ultrasound surveillance\[[@B39],[@B42]\]. In any case, it is well recognized that AFP may play an important prognostic role in the follow-up of these patients, since high AFP levels may signal more aggressive, multifocal tumors associated with venous portal thrombosis and/or metastases\[[@B43]\].

In the present study, serum AFP levels were higher in patients with HCC than in those without HCC. Nevertheless, the absence of a cutoff point with satisfactory sensitivity and specificity to detect HCC compromises the usefulness of this test. We believe that AFP dosing is more valuable to establish HCC prognosis than HCC diagnosis \[[@B44]\].

The incidence of HCC has been increasing globally, especially in the West, as a consequence of the obesity epidemic and of the growing number of patients with chronic liver disease\[[@B45]\]. In our cohort, cumulative HCC incidence was 2.6%, 15.4%, and 28.8% in the 1^st^, 5^th^, and 10^th^ year respectively, which is similar to the data reported for other cirrhotic cohorts\[[@B27],[@B46]\].

We observed that more patients were diagnosed with early stage HCC, as determined by BCLC criteria, in the presence of ultrasound monitoring at 6-mo intervals, even if survival was similar in this group, as compared to the group submitted to surveillance ultrasound at broader intervals. The difficulty in demonstrating increased survival associated with surveillance programs involves ethical issues relating to the performance of randomized, controlled trials. In this cohort, despite the lower survival of HCC patients *vs* those with cirrhosis and without HCC, there was no difference between those who underwent strict surveillance and those who did not. Sangiovanni et al\[[@B28]\] successfully demonstrated increased survival in cirrhotic patients with HCC undergoing surveillance between 1985 and 2011.

Interestingly, we observed a negative association between use of statins and development of HCC. Even though this might be a chance finding, given the low number of patients using this medication, previous studies have reported an effect of statins on patients with chronic liver disease\[[@B47]-[@B54]\]. All these previous works have described a protective effect. In fact, Chiu et al\[[@B48]\] described a reduction of 38% in the risk of HCC in patients from a surveillance program.

In conclusion, the findings of the present study underscore the high incidence of HCC in individuals with cirrhosis, highlighting the importance of stimulating the adherence of health care services and patients to surveillance programs.
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